A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.

ABSTRACT: Traditional approaches to cancer vaccines elicit weak CD8⁺ T cell responses and have largely failed to meet clinical expectations. This is in part due to inefficient antigen cross-presentation, inappropriate selection of adjuvant and its formulation, poor vaccine pharmacokinetics, and/or suboptimal coordination of antigen and adjuvant delivery. Here, we describe a nanoparticle vaccine platform for facile co-loading and dual-delivery of antigens and nucleic acid adjuvants that elicits robust antigen-specific cellular immune responses. The nanovaccine design is based on diblock copolymers comprising a poly(ethylene glycol)-rich first block that is functionalized with reactive moieties for covalent conjugation of antigen via disulfide linkages, and a pH-responsive second block for

SUBMITTER: Carson CS 

PROVIDER: S-EPMC9133199 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature